{"subsection_name": null, "pub_date": "2011-10-08T00:00:00Z", "byline": {"original": "By REUTERS", "contributor": "", "organization": "REUTERS", "person": []}, "abstract": null, "word_count": "132", "print_page": "", "news_desk": "Business", "snippet": "Teva said it expected to close the deal for Cephalon, valued at nearly $7 billion, by Oct. 14, subject to approval by the European Commission.", "multimedia": [], "source": "The New York Times", "blog": [], "keywords": [{"name": "organizations", "is_major": "N", "value": "Teva Pharmaceutical Industries Ltd", "rank": "1"}, {"name": "organizations", "is_major": "N", "value": "Cephalon Incorporated", "rank": "2"}, {"name": "subject", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "rank": "3"}, {"name": "subject", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "rank": "4"}], "type_of_material": "News", "lead_paragraph": "Teva said it expected to close the deal for Cephalon, valued at nearly $7 billion, by Oct. 14, subject to approval by the European Commission.", "web_url": "http://www.nytimes.com/2011/10/08/business/teva-agrees-to-conditions-for-merger-with-cephalon.html", "section_name": "Business Day", "headline": {"main": "Teva Agrees to Conditions for Drug Merger", "print_headline": "Teva Agrees to Conditions for Drug Merger", "seo": "Teva Agrees to Conditions for Merger With Cephalon"}, "slideshow_credits": null, "_id": "5401e56338f0d841b2f3a3ac", "document_type": "article"}